DRUGapprovedsmall molecule
atorvastatin
Approved indications
cholesterol-hyperlipidemia
Related claims (9)
| Type | Predicate | Conf | Source |
|---|---|---|---|
| pathway membership | The neuroprotective effect of atorvastatin against oxidative stress is mediated through PI3K signaling pathway activation. | 65% | 25577170 |
| neuroprotection | Atorvastatin exerts neuroprotective effects in motor neurons through free radical scavenging mechanisms. | 59% | 25577170 |
| pathway membership | The neuroprotective effect of atorvastatin against oxidative stress is mediated through ERK signaling pathway activation. | 59% | 25577170 |
| gene expression | Atorvastatin increases expression of Bcl-2, a pro-survival protein, in motor neurons under oxidative stress. | 53% | 25577170 |
| neuroprotection | Atorvastatin protects motor neuron-like cells (NSC-34D) against oxidative stress in a concentration-dependent manner. | 53% | 25577170 |
| pathway membership | Atorvastatin (Ator) induces disruption in VE-cadherin (VEC)-containing cell-cell adherens junctions (AJs) in HUVECs by enhancing Src-induced VEC internalization and RhoA/ROCK-mediated cellular contraction (in vitro). | 51% | 29730311 |
| neuroprotection | Atorvastatin decreases levels of pro-apoptotic proteins Bax, cleaved caspase-9, and cleaved caspase-3 in motor neurons under oxidative stress. | 45% | 25577170 |
| gene expression | Atorvastatin increases phosphorylation of Akt in motor neurons under oxidative stress. | 45% | 25577170 |
| gene expression | Atorvastatin increases phosphorylation of ERK in motor neurons under oxidative stress. | 45% | 25577170 |
Off-Target Findings (0)
No Boltz-2 / Chai-1 off-target panel claims recorded for this drug.